TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
Millions of patients suffer from major depressive disorder (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy. We used a pharmacometabolomics-informed pharmacogenomics research strategy to identify genes associated with metabolites that were related to SSRI respo...
Main Authors: | Gupta, M, Neavin, D, Liu, D, Biernacka, J, Hall-Flavin, D, Bobo, W V, Frye, M A, Skime, M, Jenkins, G D, Batzler, A, Kalari, K, Matson, W, Bhasin, S S, Zhu, H, Mushiroda, T, Nakamura, Y, Kubo, M, Wang, L, Kaddurah-Daouk, R, Weinshilboum, R M |
---|---|
Format: | Online |
Language: | English |
Published: |
Nature Publishing Group
2016
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003027/ |
Similar Items
-
Pharmacometabolomics Reveals Racial Differences in Response to Atenolol Treatment
by: Wikoff, William R., et al.
Published: (2013) -
Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics
by: Ji, Yuan, et al.
Published: (2012) -
Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed-Pharmacogenomics
by: Yerges-Armstrong, Laura M., et al.
Published: (2013) -
Pharmacometabolomic Assessment of Metformin in Non-diabetic, African Americans
by: Rotroff, Daniel M., et al.
Published: (2016) -
Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes
by: Rotroff, DM, et al.
Published: (2015)